All stock lists
Unlock the score
Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
Healthcare · Biotechnology
21.68+0.24 (+1.12%)
Insider Score
/ 100
BRVE Insider Score
Braveheart Bio, Inc. has a live Insider Score.
Scored on 10 qualifying trades from 8 insiders in the last 90 days.
BRVE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | — | 0.00 | — |
| Revenue Growth (YoY) | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| SG&A Expense | 4.76 M | — | 27.00 K | — |
| R&D Expense | 11.13 M | — | 0.00 | — |
| Operating Expenses | 15.88 M | — | 27.00 K | — |
| Operating Income | -15.88 M | — | -27.00 K | — |
| Pretax Income | -14.99 M | — | -381.00 K | — |
| Tax Provision | — | — | — | — |
| Net Income | -14.99 M | — | -381.00 K | — |
| EPS (Basic) | -0.25 | -0.33 | -0.01 | -0.00 |
| EPS (Diluted) | -0.25 | -0.33 | -0.01 | -0.00 |
| Shares Outstanding | 73.15 M | 42.82 M | 42.82 M | 42.82 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.